# Designs for Vaccine Studies

**Authors:** M. Elizabeth Halloran

PMC · DOI: 10.1146/annurev-statistics-033121-120121 · Annual review of statistics and its application · 2025-05-16

## TL;DR

This paper discusses various study designs used to evaluate vaccines, including their direct and indirect effects on populations.

## Contribution

The paper highlights recent developments in vaccine study designs, such as target trial emulation and ring vaccination.

## Key findings

- Vaccination can have indirect effects on unvaccinated individuals.
- The ring vaccination trial design was first used during the Ebola outbreak.
- Methods for evaluating vaccine durability were developed for both blinded and unblinded studies.

## Abstract

Due to dependent happenings, vaccines can have different effects in populations. In addition to direct protective effects in the vaccinated, vaccination in a population can have indirect effects in the unvaccinated individuals. Vaccination can also reduce person-to-person transmission to vaccinated individuals or from vaccinated individuals compared with unvaccinated individuals. Design of vaccine studies has a history extending back over a century. Emerging infectious diseases, such as the SARS-CoV-2 pandemic and the Ebola outbreak in West Africa, have stimulated new interest in vaccine studies. We focus on some recent developments, such as target trial emulation, test-negative design, and regression discontinuity design. Methods for evaluating durability of vaccine effects were developed in the context of both blinded and unblinded placebo crossover studies. The case-ascertained design is used to assess the transmission effects of vaccines. The novel ring vaccination trial design was first used in the Ebola outbreak in West Africa.

## Linked entities

- **Diseases:** SARS-CoV-2 (MONDO:0100096), Ebola (MONDO:0005737)

## Full-text entities

- **Diseases:** RANDOMIZED (MESH:C562757), dengue (MESH:D003715), IMMUNE CORRELATES (MESH:D007154), infected (MESH:D007239), Infectious Diseases (MESH:D003141), malaria (MESH:D008288), Diphtheria (MESH:D004165), death (MESH:D003643), acute (MESH:D000208), INDIRECT (MESH:D051556), acute respiratory infection (MESH:D012141), COVID-19 (MESH:D000086382), influenza (MESH:D007251), Marburg infection (MESH:D008379), SAR (MESH:D000068376), cough (MESH:D003371), VACCINE EFFECTS (MESH:D004673), pertussis (MESH:D014917), TRANSMISSION (MESH:D017096), TOTAL (MESH:C535338), tetanus toxoid (MESH:D013746), Ebola (MESH:D019142), cholera (MESH:D002771), IPV (MESH:D011051), respiratory illness (MESH:D012140)
- **Chemicals:** DTaP (-)
- **Species:** Human immunodeficiency virus 1 (no rank) [taxon 11676], H3N2 subtype (serotype) [taxon 119210], Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Marburg virus [taxon 186537], Ebola virus (no rank) [taxon 1570291], Rotavirus (genus) [taxon 10912], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12083782/full.md

## References

54 references — full list in the complete paper: https://tomesphere.com/paper/PMC12083782/full.md

---
Source: https://tomesphere.com/paper/PMC12083782